Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Check out our top picks below. If you are looking for a powerful allergy nasal spray that provides 24-hour all-in-one relief for even your worst seasonal, year-round, indoor, and outdoor allergy ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone ... and can reduce symptoms in as little as 24 hours. Johnson & Johnson said that because there ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...